CareDx launches AlloSeq® cfDNA at ESOT 2019
AlloSeq cfDNA has been utilized by beta sites in 4 countries, and is now broadly available for transplant patients outside of the US. The 19th
“Cell-free DNA is starting to change clinical practice in the US; it offers a more accurate assessment than any of the currently available non-invasive tests for monitoring graft health,” said
“Expanding access to AlloSeq cfDNA for transplant patients internationally follows our strong commitment to improve outcomes for all transplant patients,” said
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements, including statements regarding the launch of the Company’s new kit-based dd-cfDNA surveillance test AlloSeq cfDNA and statements regarding the impact of cell-free DNA on the clinical practice. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks related to the launch of the new test AlloSeq cfDNA and clinical practices in the US and internationally, among others discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed by CareDx with the SEC on March 6, 2019 and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Chief Marketing Officer,
Chief Financial Officer,
Source: CareDx, Inc.